P2RY12 and acute coronary syndrome: As only the patients with clopidogrel usage were enrolled, a possible selection bias in patients with acute coronary syndrome with other potent P2Y12 inhibitors remains; patients who were prescribed with the more potent P2Y12 inhibitors, either before or after enrollment, were excluded from the registry.